Calchan and Galapagos team up on osteoarthritic pain therapies
UK-based Calchan Holdings, a company focused on developing medicines based on calcium ion channel modulators, and Belgian biotech firm Galapagos NV (Euronext: GLPG), a clinical-stage company focused on developing new modes of action medicines, have entered into a research collaboration in osteoarthritic pain.
The UK’s innovation agency, Innovate UK, has awarded Calchan with a grant of £2.4 million ($3.9 million) for Biomedical Catalyst Early Stage Round 2 to discover and develop compounds against a novel target for osteoarthritic pain.
The two companies will collaborate to identify preclinical candidates. Subsequently, Calchan and Galapagos may jointly progress the assets further into the clinic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze